The Vascular Biology and Transplantation Program

The Program in Vascular Biology and Transplantation was launched in 2000 as an interdisciplinary effort to apply research in vascular biology to the problems associated with organ repair and replacement therapies. The initial targets of VBT were identified as arteriosclerosis as a cause of late grafts failure (chronic vascular rejection), vascular incompatibilities underlying pig-into-human xenotransplantation, and strategies to revascularize organs failing due to ischemia. In the last few years, the emphasis on graft vessel arteriosclerosis has widened to include pathologies associated with other, more common forms of arteriosclerosis (such as atherosclerosis) and emphasis has shifted from xenotransplantation as a source of replacement organs to the application of vascular biology to improved tissue engineering of replacement human organs. The VBT Program currently has thirty-five faculty members in a number of departments, including Medicine, Surgery, Neurosurgery, Anesthesiology, Pathology, Pharmacology, Immunobiology, Physiology, Comparative Medicine and Biomedical Engineering.

VBT is the first program developed at Yale Medical School with the explicit goal of building teams of interactive investigators to conduct translational research. Its success has encouraged the School of Medicine to foster similar programs to address autoimmune and inflammatory diseases.

Modal Title

How will my information be used?

When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.

If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.

In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.